| James Robert Feher, MSN, APRN, FNP-C | |
|
4077 Elm Springs Rd Ste 105, Springdale, AR 72762-3703 | |
| (479) 927-2100 | |
| Not Available |
| Full Name | James Robert Feher |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 4077 Elm Springs Rd Ste 105, Springdale, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043704497 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A005687 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Siloam Springs Regional Hospital | Siloam springs, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Roller Weight Loss Institute, Inc. | 0446398770 | 22 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Entity Name | Northwest Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194768721 PECOS PAC ID: 0244213213 Enrollment ID: O20040610000882 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Entity Name | Northwest Benton County Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871553073 PECOS PAC ID: 3577503689 Enrollment ID: O20050509000505 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Entity Name | Siloam Springs Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013155431 PECOS PAC ID: 9032275318 Enrollment ID: O20090312000025 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Entity Name | Roller Weight Loss Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073743399 PECOS PAC ID: 0446398770 Enrollment ID: O20091106000368 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Entity Name | Fayetteville Arkansas Hospital Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902267875 PECOS PAC ID: 1052619814 Enrollment ID: O20160601000627 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Robert Feher, MSN, APRN, FNP-C 404 Sw 11th St, Bentonville, AR 72712-6278 Ph: (423) 718-4487 | James Robert Feher, MSN, APRN, FNP-C 4077 Elm Springs Rd Ste 105, Springdale, AR 72762-3703 Ph: (479) 927-2100 |
News Archive
Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung
A University of Colorado Cancer Center study recently published in the Journal of Hospital Medicine validates a prognostic tool that determines risk of death within a year of hospital admission, helping doctors match treatments to patients' values and goals of care.
Audentes Therapeutics, Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing.
› Verified 3 days ago
Katherine A Darling, DNP, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2400 S 48th St, Springdale, AR 72762 Phone: 479-750-2020 Fax: 479-750-4843 | |
Scott Grigg, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4301 Greathouse Springs Rd, Springdale, AR 72762 Phone: 479-684-3132 Fax: 479-684-3098 | |
Andrew Long, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 609 W Maple Ave, Springdale, AR 72764 Phone: 479-751-5711 | |
Kaylee M Armendariz, APRN-CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2878 Powell St, Springdale, AR 72764 Phone: 479-872-3045 Fax: 479-419-5947 | |
Kelsey Breanne Smith, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 210 S Thompson St Ste 4a, Springdale, AR 72764 Phone: 479-445-9900 | |
Stephanie Burks, FNP-CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 210 S Thompson St Ste 4a, Springdale, AR 72764 Phone: 479-445-9900 |